GlassScriptPhysician profile
Abdallah Al-Shahed
NPI 1639159528
$1,593.19
in general payments reported to CMS, 2019-2025
14 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.22 · 2020: $12.00 · 2021: $19.10 · 2022: $487 · 2023: $752 · 2024: $97.96 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $574.72 | 2022-2024 | Briviact, Nayzilam, Fintepla |
| Bayer Healthcare Pharmaceuticals INC. | $290.19 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $267.60 | 2023-2024 | |
| Genzyme Corporation | $107.07 | 2025 | |
| Neurelis, INC. | $82.57 | 2023-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $65.31 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $41.48 | 2023-2024 | Nuedexta |
| Lundbeck LLC | $37.59 | 2023 | Rexulti |
| Urgo Medical North America, LLC | $27.40 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Astellas Pharma US INC | $26.57 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $21.87 | 2023 | Bexsero |
| Novartis Pharmaceuticals Corporation | $19.72 | 2023 | |
| Eisai INC. | $19.10 | 2021 | |
| Amarin Pharma, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Al-Shahed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.